Altimmune, Inc. (ALT) stock plummeted 10.64% during Friday's intraday trading session despite the company presenting encouraging new data from its Phase 1b trial of pemvidutide in metabolic dysfunction-associated steatotic liver disease (MASH).
The data, presented at The Liver Meeting® 2024 of the American Association for the Study of Liver Diseases, showed that once-weekly subcutaneous doses of pemvidutide resulted in significant reductions in multiple classes of inflammatory lipids associated with increased cardiovascular disease risk and atherosclerosis progression.
Specifically, pemvidutide rapidly and markedly reduced levels of small atherogenic LDL particles compared to placebo in MASH patients with overweight or obesity. These findings suggest pemvidutide could potentially help address major comorbidities of MASH beyond just reducing liver fat, such as cardiovascular disease, atherosclerosis, and metabolic syndrome.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。